However, when combined with other drugs, including epigenetic drugs that suppress CCR2 expression by MDSCs, the treatment synergistically prolonged mice survival after tumor resection.5 The CCR2 inhibitor (BMS-813160) is under clinical evaluation, in combination with immunotherapy or chemotherapy against solid cancers (NCT03496662, NCT03767582, NCT04123379). The gene discussed is CCR2; the disease is neoplasm.